North Carolina Headlines

DelveInsight’s “IgA Nephropathy Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the IgA Nephropathy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the IgA Nephropathy Pipeline? @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

Key Takeaways from the IgA Nephropathy Pipeline Report

• On June 08, 2026- ADARx Pharmaceuticals Inc. announced a Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
• On June 03, 2026- Otsuka Pharmaceutical Development & Commercialization, Inc. highlighted a phase 3 study to evaluate the efficacy and safety of sibeprenlimab 400 mg administered SC Q 4 weeks compared to placebo in patients with IgAN. The primary objective is to compare the relative change from baseline in the urinary protein to creatinine ratio (uPCR) in 24-hour urine collections, after 9 months of treatment.
• On June 02, 2026- Takeda conducted a study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn’t have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.
• On June 01, 2026- Novartis Pharmaceuticals initiated AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
• DelveInsight’s IgA Nephropathy Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for IgA Nephropathy treatment.
• The leading IgA Nephropathy Companies such as Novartis Pharmaceuticals, Biohaven Ltd., Keymed Biosciences Co. Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., ADARx Pharmaceuticals Inc., Biogen, Suzhou Rigerna Therapeutics, Wuxi BioCity Biopharmaceutics Co., Ltd., Transcenta Holding, Climb Bio, Chengdu Suncadia Medicine Co., Ltd., Purespring Therapeutics and others.
• Promising IgA Nephropathy Therapies such as LNP023, Blisibimod, HR19042 Capsules, Telitacicept, Intravenous Rituximab, Nefecon, BION-1301, Atrasentan, and others.

Want to know which companies are leading innovation in IgA Nephropathy? @ IgA Nephropathy Clinical Trials Assessment

The IgA Nephropathy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The IgA Nephropathy Pipeline Report also highlights the unmet needs with respect to the IgA Nephropathy.

IgA Nephropathy Overview

IgA nephropathy (IgAN), or Berger’s disease, is the most common primary glomerular disease that can progress to end stage renal failure (ESRD). Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. This condition most often occurs in Caucasian and Asian males. It usually appears when people are in their teens to late 30s but can occur at any age. Many cases resolve over time. However, in a subset of patients, the disease may not resolve and thus can lead to end-stage renal disease (ESRD) after 20-25 years. Rarely the condition can progress much more rapidly leading to renal failure within a few years, if not treated.

IgA Nephropathy Emerging Drugs Profile

• Zigakibart (BION-1301): Novartis Pharmaceuticals

Zigakibart is a humanized IgG4 monoclonal antibody that binds the cytokine A Proliferation-Inducing Ligand (APRIL, also known as TNFSF13). APRIL is a critical factor in immunoglobulin (Ig) A nephropathy pathogenesis. By targeting APRIL, zigakibart interferes with B-cell differentiation and the survival of Gd-IgA1–producing plasma cells, thereby leading to decreased Gd-IgA1 levels and consequently reducing immune complex formation, thus exhibiting disease-modifying potential in IgAN. Novartis Pharmaceuticals is currently investigating Zigakibart in Phase III clinical trials for IgA Nephropathy.

• BHV-1400: Biohaven, Ltd.

BHV-1400 is a potential first-in-class Gd-IgA1 TRAP degrader, rationally designed to leverage the body’s natural hepatic clearance mechanisms to selectively target and remove Gd-IgA1, the underlying cause of the IgA nephropathy and IgA vasculitis. BHV-1400 spares IgG, IgA, IgE, and IgM to preserve patient immune protection against bacteria, viruses and parasites. Currently, according to the company’s pipeline the drug is being evaluated in the Phase I/II stage of its development for the treatment of IgA Nephropathy.

• TST 008: Transcenta Holding

TST 008 is a first-in-class bispecific antibody combining MASP2 antibody with another molecule blocking B-cell activation and/or differentiation. It act as Immunogenetic modulators. It acts by targeting both the lectin complement pathway and B-cell regulation pathway. TST008 binds to Mannan-binding lectin-associated serine protease-2 (MASP2). By blocking MASP2, TST008 inhibits the lectin pathway of the complement cascade, which is involved in driving inflammatory processes in autoimmune diseases. The molecule is fused with a truncated transmembrane activator and calcium modulator ligand interactor (TACI) protein. This TACI component allows the antibody to bind to ligands such as BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). The drug is being evaluated in preclinical stage of its development for the treatment of IgA Nephropathy.

If you’re tracking ongoing IgA Nephropathy Clinical trials, this press release is a must-read @ IgA Nephropathy Treatment Drugs

The IgA Nephropathy Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
• IgA Nephropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

IgA Nephropathy Companies

Novartis Pharmaceuticals, Biohaven Ltd., Keymed Biosciences Co. Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., ADARx Pharmaceuticals Inc., Biogen, Suzhou Rigerna Therapeutics, Wuxi BioCity Biopharmaceutics Co., Ltd., Transcenta Holding, Climb Bio, Chengdu Suncadia Medicine Co., Ltd., Purespring Therapeutics and others.

IgA Nephropathy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

IgA Nephropathy Products have been categorized under various Molecule types such as,

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the IgA Nephropathy Pipeline Report covers it all @ IgA Nephropathy Market Drivers and Barriers, and Future Perspectives

Scope of the IgA Nephropathy Pipeline Report

• Coverage- Global
• IgA Nephropathy Companies- Novartis Pharmaceuticals, Biohaven Ltd., Keymed Biosciences Co. Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., ADARx Pharmaceuticals Inc., Biogen, Suzhou Rigerna Therapeutics, Wuxi BioCity Biopharmaceutics Co., Ltd., Transcenta Holding, Climb Bio, Chengdu Suncadia Medicine Co., Ltd., Purespring Therapeutics and others.
• IgA Nephropathy Therapies- LNP023, Blisibimod, HR19042 Capsules, Telitacicept, Intravenous Rituximab, Nefecon, BION-1301, Atrasentan, and others.
• IgA Nephropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• IgA Nephropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the IgA Nephropathy Treatment landscape in this detailed analysis @ IgA Nephropathy Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. IgA Nephropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. IgA Nephropathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Zigakibart (BION-1301): Novartis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. BHV-1400: Biohaven, Ltd.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TST 008: Transcenta Holding
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. IgA Nephropathy Key Companies
21. IgA Nephropathy Key Products
22. IgA Nephropathy- Unmet Needs
23. IgA Nephropathy- Market Drivers and Barriers
24. IgA Nephropathy- Future Perspectives and Conclusion
25. IgA Nephropathy Analyst Views
26. IgA Nephropathy Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight